Recent News

• 03.04.2026 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.26.2026 - BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
• 02.17.2026 - BioCryst to Present at Upcoming Investor Conference
• 02.11.2026 - BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
• 02.05.2026 - BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
• 02.05.2026 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 01.23.2026 - BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

Recent Filings

• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.02.2026 - 144 Report of proposed sale of securities
• 02.26.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.26.2026 - 8-K Current report
• 02.26.2026 - EX-99.1 EX-99.1
• 02.12.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors